← Browse by Condition
Medical Condition

thrombocytopenia

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 4

ClinicalMetric tracks all active clinical trials for thrombocytopenia sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — thrombocytopenia Clinical Trials

How many clinical trials are currently recruiting for thrombocytopenia?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for thrombocytopenia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for thrombocytopenia?
thrombocytopenia research spans Phase 1 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a thrombocytopenia clinical trial?
Eligibility criteria for thrombocytopenia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 4
1
Top Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1 trial
Tzu-Fei Wang 1 trial
University Hospital, Bordeaux 1 trial

Recruiting Clinical Trials

NCT06245746 Phase 1
Recruiting
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Enrollment
9 pts
Location
China
Sponsor
Union Hospital, Tongji Medical...
View Trial →
NCT05255003 Phase 4
Recruiting
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Enrollment
50 pts
Location
Canada
Sponsor
Tzu-Fei Wang
View Trial →
NCT04800458
Recruiting
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Enrollment
225 pts
Location
France
Sponsor
University Hospital, Bordeaux
View Trial →

Related Conditions

acute myeloid leukemia (1) neutropenia (1) anemia (1) infections (1) bleeding (1) cancer associated thrombosis (1) immune thrombocytopenia (1) myelodysplasia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology